LUTATHERA (lutetium LU 177 dotatate)
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $978,418 | 79 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $978,418 | 79 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours | Advanced Accelerator Applications | $530,933 | 1 |
| Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | Advanced Accelerator Applications | $430,198 | 0 |
Top Doctors Receiving Payments for LUTATHERA (lutetium LU 177 dotatate)
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Kettering, OH | $969,157 | 73 |
| Stanley Garbus | — | Edgewater, NJ | $9,261 | 6 |
Manufacturing Companies
- Advanced Accelerator Applications $978,418
Product Information
- Type Drug
- Total Payments $978,418
- Total Doctors 1
- Transactions 79
About LUTATHERA (lutetium LU 177 dotatate)
LUTATHERA (lutetium LU 177 dotatate) is a drug associated with $978,418 in payments to 1 healthcare providers, recorded across 79 transactions in the CMS Open Payments database. The primary manufacturer is Advanced Accelerator Applications.
Payment data is available from 2017 to 2017. In 2017, $978,418 was paid across 79 transactions to 1 doctors.
The most common payment nature for LUTATHERA (lutetium LU 177 dotatate) is "Unspecified" ($978,418, 100.0% of total).
LUTATHERA (lutetium LU 177 dotatate) is associated with 2 research studies, including "A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours" ($530,933).